Biogen and Denali discontinue BIIB122 development after Phase 2b failure in Parkinson's

The Phase 2b LUMA study of BIIB122 failed to meet primary and secondary endpoints in early-stage Parkinson's disease, prompting discontinuation in idiopathic PD while continuing a separate LRRK2 carrier study. The setback represents a significant clinical disappointment for both companies in the neurodegenerative disease space.